ALK and non-small cell lung carcinoma: In this study, a panel of lung cancer models harboring a range of oncogenic mutations, MYC amplifications, and the fusion protein EML4-ALK, representing the most relevant clinical subtypes of NSCLC or SCLC were selected to evaluate the biological relevance of BET inhibition in lung cancer and to better define which subtypes have the potential to be more sensitive to BET inhibition.